New investigator-initiated Phase II trial for Efti
Filed with ASX · · 2 pages · English
Story so far
- Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
- Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
- Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
Earlier from Immutep
- Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
- Appendix 4E & 2025 Full Year Statutory Accounts
- Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
- FDA feedback received for head & neck cancer in CPS below 1
- Immutep Quarterly Activities Report Q4 FY25
Later from Immutep
- Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
- TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC
- Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
- Successful Completion of FDA Project Optimus Requirements
- Immutep Announces Successful Completion of FDA Project Optimus Requirements
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep